CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Carlyle and PAI Partners agree to sell pharma company Theramex to Cinven

By Reuters News10:14 (UTC), 3 November 2026 Updated

Nov 3 (Reuters) - Carlyle CG.O and PAI Partners have agreed to sell pharmaceuticals company Theramex to rival private equity company Cinven, the companies announced on Tuesday.

• London-headquartered company Theramex is a leading global specialty pharmaceutical company focused on women's health.

• Theramex offers a diversified portfolio of treatments across menopause, osteoporosis, contraception, uterine health and fertility.

• The companies did not disclose the financial terms of the transaction, although the Financial Times reported earlier that the sale deal was worth 2.6 billion euros ($2.9 billion).

• "With Cinven, we have the right partner for our next chapter, and we share an ambition to become the global leader in women's health," said Theramex CEO Robert Stewart in a statement.

($1 = 0.8937 euros)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.